Evidence map›Paper›PMID 36800014›Full record

ArticleNaunyn-Schmiedeberg's archives of pharmacology2023

Pirfenidone affects human cardiac fibroblast proliferation and cell cycle activity in 2D cultures and engineered connective tissues.

Friederike Elisabeth Ugi Meyer, Gabriela Leao Santos, Thao Phuong Doan, Alisa Nicole DeGrave, Bastian Bues, Susanne Lutz

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Friederike Elisabeth Ugi MeyerInstitute of Pharmacology and Toxicology, University Medical Center, Goettingen, Germany.
Gabriela Leao SantosInstitute of Pharmacology and Toxicology, University Medical Center, Goettingen, Germany.
Thao Phuong DoanInstitute of Pharmacology and Toxicology, University Medical Center, Goettingen, Germany.
Alisa Nicole DeGraveInstitute of Pharmacology and Toxicology, University Medical Center, Goettingen, Germany.
Bastian BuesInstitute of Pharmacology and Toxicology, University Medical Center, Goettingen, Germany.
Susanne LutzInstitute of Pharmacology and Toxicology, University Medical Center, Goettingen, Germany. Susanne.Lutz@med.uni-goettingen.de.
German Centre for Cardiovascular Research · DEUniversity of Göttingen · DE

Funding

Deutsche Forschungsgemeinschaft IRTG1816
6 · The paper itself

Abstract

The anti-fibrotic drug pirfenidone (PFD) is currently in clinical testing for the treatment of heart failure with preserved ejection fraction; however, its effects on human cardiac cells have not been fully investigated. Therefore, we aimed to characterize the impact of PFD on human cardiac fibroblasts (CF) in 2D culture as well as in 3D-engineered connective tissues (ECT). We analyzed proliferation by automated cell counting and changes in signaling by immunoblotting. We generated ECT with different geometries to modify the cellular phenotype and investigated the effects of PFD on cell number and viability as well as on cell cycle activity. We further studied its effect on ECT compaction, contraction, stiffening, and strain resistance by ECT imaging, pole deflection analysis, and ultimate tensile testing. Our data demonstrate that PFD inhibits human CF proliferation in a concentration-dependent manner with an IC

Indexed as

Connective TissueFibroblastsCell CycleCell ProliferationFibrosisHumansPyridonespirfenidonePyridonesAnti-fibrotic drugsCardiac fibrosisEngineered connective tissuesHuman cardiac fibroblastsPirfenidone

Identifiers

PMID36800014
PMCPMC10338590
OpenAlexW4321168522

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.